RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidubicel-onlv)

Contributed by: Business Wire

Logo

Tags

Pharmaceutical

Oncology

Infectious Diseases

Other Manufacturing

Genetics

Health Technology

Clinical Trials

Cardiology

Biotechnology

Stem Cells

FDA

Health

Manufacturing

RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership

More Like This

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta

RoslinCT Awarded £7.25 million Scottish Enterprise R&D Grant to Advance Digital Cell Therapy Manufacturing

The IRO platform

Ori Biotech Announces 10-year, $120M Partnership to Advance Automated Manufacturing for Commercial Cell Therapies

CCRM, OmniaBio and Avectas Partner to Improve Cell Therapy Manufacturing

RoslinCT Announces Appointment of Jessica Carmen as Chief Commercial Officer

Ori Biotech Announces First Customer Deliveries of IRO to Leading CDMOs and Commercial CGT Manufacturers

ViroCell Biologics Completes Oversubscribed Financing